RT Journal Article
SR Electronic
T1 HER2 testing in the UK: further update to recommendations
JF Journal of Clinical Pathology
JO J Clin Pathol
FD BMJ Publishing Group Ltd and Association of Clinical Pathologists
SP 818
OP 824
DO 10.1136/jcp.2007.054866
VO 61
IS 7
A1 R A Walker
A1 J M S Bartlett
A1 M Dowsett
A1 I O Ellis
A1 A M Hanby
A1 B Jasani
A1 K Miller
A1 S E Pinder
YR 2008
UL http://jcp.bmj.com/content/61/7/818.abstract
AB These guidelines update the previous UK HER2 testing guidelines and have been formulated to give advice on methodology, interpretation and quality assurance to ensure that HER2 testing results are accurate, reliable and timely with the expansion of testing to all patients with breast cancer at the time of primary diagnosis. The recommendations for testing are the use of immunohistochemistry but with analysis of equivocal cases by in situ hybridisation to clarify their HER2 status or the use of frontline fluorescence in situ hybridisation (FISH) testing for those laboratories wishing to do so; the inclusion of a chromosome 17 probe is strongly recommended. Laboratories using chromogenic or silver in situ hybridisation should perform an initial validation against FISH. For immunohistochemistry and in situ hybridisation there must be participation in the appropriate National External Quality Assurance scheme.